Deciphera Pharmaceuticals Llc Stock Cash Flow From Operations
Deciphera Pharmaceuticals LLC fundamentals help investors to digest information that contributes to Deciphera Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Deciphera Stock. The fundamental analysis module provides a way to measure Deciphera Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Deciphera Pharmaceuticals stock.
Deciphera |
Deciphera Pharmaceuticals LLC Company Cash Flow From Operations Analysis
Deciphera Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Deciphera Pharmaceuticals Cash Flow From Operations | (146.7 M) |
Most of Deciphera Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Deciphera Pharmaceuticals LLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Deciphera Pharmaceuticals LLC has (146.7 Million) in Cash Flow From Operations. This is 127.82% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 115.1% higher than that of the company.
Deciphera Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Deciphera Pharmaceuticals' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Deciphera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Deciphera Pharmaceuticals by comparing valuation metrics of similar companies.Deciphera Pharmaceuticals is currently under evaluation in cash flow from operations category among its peers.
Deciphera Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.27 | |||
| Profit Margin | (1.09) % | |||
| Operating Margin | (1.09) % | |||
| Current Valuation | 1.97 B | |||
| Shares Outstanding | 86.48 M | |||
| Shares Owned By Insiders | 28.48 % | |||
| Shares Owned By Institutions | 72.03 % | |||
| Number Of Shares Shorted | 3.92 M | |||
| Price To Earning | (6.78) X | |||
| Price To Book | 7.00 X | |||
| Price To Sales | 12.65 X | |||
| Revenue | 163.36 M | |||
| Gross Profit | (62.55 M) | |||
| EBITDA | (210.96 M) | |||
| Net Income | (194.94 M) | |||
| Cash And Equivalents | 383.85 M | |||
| Cash Per Share | 5.74 X | |||
| Total Debt | 25.88 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 6.02 X | |||
| Book Value Per Share | 3.85 X | |||
| Cash Flow From Operations | (146.7 M) | |||
| Short Ratio | 1.05 X | |||
| Earnings Per Share | (2.21) X | |||
| Price To Earnings To Growth | (0.32) X | |||
| Target Price | 27.52 | |||
| Number Of Employees | 355 | |||
| Beta | 0.18 | |||
| Market Capitalization | 2.21 B | |||
| Total Asset | 473.57 M | |||
| Retained Earnings | (1.43 B) | |||
| Working Capital | 280.82 M | |||
| Current Asset | 70.55 M | |||
| Current Liabilities | 5.98 M | |||
| Net Asset | 473.57 M |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Deciphera Stock
If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |